[CUA analysis in new drug evaluation: a review of available tools].
Cost utility analysis (CUA) is a peculiar kind of efficacy evaluation. The outcome is the quality adjusted years of life derived by comparing an intervention versus a comparator. We review literature analyzing some criticism emerging from Cost Utility evaluation as selection bias or eventual methodological inconsistency. We applied this model to a new drug--Macugen--assessing an incremental cost of 7258.68 euro for a two years treatment schedule. Our analysis suggest that CUA is potential informative especially in certain context as prevention, but efficacy assessment and robust outcomes measuring is crucial.
Rubba
F
F
Dipartimento di Scienze Mediche Preventive, Università Federico II, Napoli. fabiana.rubba@unina.it
Panico
S
S
Cuccaro
P
P
della
Vecchia A
VA
Paudice
A
A
Triassi
M
M
D003362:Cost-Benefit Analysis / Q000379:methods; D004341:Drug Evaluation / Q000191:economics*; D006801:Humans